Connect public, paid and private patent data with Google Patents Public Datasets

Compositions and methods for generating chimeric heteromultimers

Info

Publication number
WO2003012069A3
WO2003012069A3 PCT/US2002/024582 US0224582W WO2003012069A3 WO 2003012069 A3 WO2003012069 A3 WO 2003012069A3 US 0224582 W US0224582 W US 0224582W WO 2003012069 A3 WO2003012069 A3 WO 2003012069A3
Authority
WO
Grant status
Application
Patent type
Prior art keywords
invention
binding
units
antigen
technique
Prior art date
Application number
PCT/US2002/024582
Other languages
French (fr)
Other versions
WO2003012069A2 (en )
Inventor
Caili Wang
Pingyu Zhong
Shengjiang Liu
Peizhi Luo
Shengfeng Li
Xinwei Wang
Original Assignee
Abmaxis Inc
Caili Wang
Pingyu Zhong
Shengjiang Liu
Peizhi Luo
Shengfeng Li
Xinwei Wang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Abstract

The present invention provides a technique for specific assembly of monomericpolypeptides to form a heteromultimer. This technique is particularly useful for generating a genetically diverse repertoire of heteromultimers such as antigen-binding units. The invention also provides both non-single-chain and single-chain antigen-binding units that are assembled by the technique described herein. The present invention also provides recombinant polynucleotides, vectors, host cells, and kits for producing the subjectantigen-binding units. Further provided by the invention are methods of using the subject antigen-binding units.
PCT/US2002/024582 2001-08-01 2002-07-31 Compositions and methods for generating chimeric heteromultimers WO2003012069A3 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US09921144 US6833441B2 (en) 2001-08-01 2001-08-01 Compositions and methods for generating chimeric heteromultimers
US09/921,144 2001-08-01

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA 2455237 CA2455237C (en) 2001-08-01 2002-07-31 Compositions and methods for generating chimeric heteromultimers
EP20020763414 EP1421117B1 (en) 2001-08-01 2002-07-31 Compositions and methods for generating chimeric heteromultimers
JP2003517247A JP2005506064A (en) 2001-08-01 2002-07-31 Compositions and methods for the production of the chimeric heteromultimer

Publications (2)

Publication Number Publication Date
WO2003012069A2 true WO2003012069A2 (en) 2003-02-13
WO2003012069A3 true true WO2003012069A3 (en) 2003-11-06

Family

ID=25444981

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/024582 WO2003012069A3 (en) 2001-08-01 2002-07-31 Compositions and methods for generating chimeric heteromultimers

Country Status (6)

Country Link
US (2) US6833441B2 (en)
JP (2) JP2005506064A (en)
CN (2) CN1558916A (en)
CA (1) CA2455237C (en)
EP (1) EP1421117B1 (en)
WO (1) WO2003012069A3 (en)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018749A3 (en) * 2001-08-22 2003-11-06 Shengfeng Li Compositions and methods for generating antigen-binding units
WO2003066660A3 (en) * 2002-02-05 2004-12-09 Nigel Robert Caterer A PAIR OF ANTIBODY Fv FRAGMENTS STABILIZED BY COILED­COIL PEPTIDES
US20030157091A1 (en) * 2002-02-14 2003-08-21 Dyax Corporation Multi-functional proteins
US20040067532A1 (en) * 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
US20050147962A1 (en) * 2002-11-19 2005-07-07 Wagstrom Christopher R. Display of dimeric proteins on phage
US20050131219A1 (en) * 2003-08-18 2005-06-16 Urdea Michael S. Methods for reducing complexity of a sample using small epitope antibodies
JP2007008925A (en) * 2005-05-31 2007-01-18 Canon Inc Target substance-catching molecule
US8299032B2 (en) * 2005-06-27 2012-10-30 Menicon Co., Ltd. Self-assembling peptide and gel produced from the same
JP5199876B2 (en) * 2005-10-21 2013-05-15 アムジェン インコーポレイテッド Method for generating a monovalent IgG
GB0525918D0 (en) * 2005-12-20 2006-02-01 Sharp Kk A method of producing a multimeric capture agent for binding a ligand
GB0525915D0 (en) * 2005-12-20 2006-02-01 Sharp Kk Novel capture agents for binding a ligand
GB0525916D0 (en) * 2005-12-20 2006-02-01 Sharp Kk Method for functionalising a hydrophobic substrate
US8097425B2 (en) * 2006-03-10 2012-01-17 Tethys Bioscience, Inc. Multiplex protein fractionation
EP1999154B1 (en) 2006-03-24 2012-10-24 Merck Patent GmbH Engineered heterodimeric protein domains
JP2009541275A (en) * 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー/エス Production of bispecific antibody
US7932055B2 (en) * 2006-06-22 2011-04-26 Novo Nordisk A/S Soluble heterodimeric CD94/NKG2 receptors fusion proteins
EP2471816A1 (en) * 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
FI120376B (en) * 2007-01-17 2009-09-30 Next Biomed Technologies Nbt O The method of Bioengineered, the high affinity of the polypeptide for the preparation of
FI120349B (en) 2007-03-07 2009-09-30 Next Biomed Technologies Nbt O Process for the preparation of a fusion polypeptide
RU2010102859A (en) 2007-08-21 2011-09-27 Морфосис Аг (De) Improved methods for the formation of disulfide bonds
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
JP5933894B2 (en) 2007-09-14 2016-06-15 アディマブ, エルエルシー Rationally designed, synthesized antibody libraries and uses thereof
DK2205968T3 (en) 2007-10-02 2014-02-17 Theranos Inc Modular POC (point of care) Devices and uses thereof
US8637435B2 (en) * 2007-11-16 2014-01-28 Merck Sharp & Dohme Corp. Eukaryotic cell display systems
WO2009111183A1 (en) 2008-03-03 2009-09-11 Glycofi, Inc. Surface display of recombinant proteins in lower eukaryotes
ES2628108T3 (en) 2008-09-03 2017-08-01 F Hoffmann-La Roche Ag multispecific antibodies
RU2598248C2 (en) 2009-04-02 2016-09-20 Роше Гликарт Аг Polyspecific antibodies containing antibody of full length and one-chain fragments fab
CN102459346B (en) * 2009-04-27 2016-10-26 昂考梅德药品有限公司 A method for producing a heterologous multimeric molecule
US20120302737A1 (en) * 2009-09-16 2012-11-29 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
EP2325311A1 (en) * 2009-11-18 2011-05-25 Pierre Fabre Medicament Novel phage display vector
US8802091B2 (en) 2010-03-04 2014-08-12 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
KR20130010117A (en) 2010-03-04 2013-01-25 마크로제닉스, 인크. Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
CN103282560B (en) 2010-07-16 2016-08-03 阿迪马布有限责任公司 Antibody library
US20130245233A1 (en) 2010-11-24 2013-09-19 Ming Lei Multispecific Molecules
CN106290159A (en) 2011-01-21 2017-01-04 提拉诺斯公司 Systems and methods for sample use maximization
US9499605B2 (en) 2011-03-03 2016-11-22 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
EP2742069A4 (en) * 2011-08-10 2015-04-01 Korea Advanced Inst Sci & Tech Amphipathic peptide-lipase conjugate having advanced lipase activity and use thereof
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
US9632102B2 (en) 2011-09-25 2017-04-25 Theranos, Inc. Systems and methods for multi-purpose analysis
US8475739B2 (en) 2011-09-25 2013-07-02 Theranos, Inc. Systems and methods for fluid handling
US9268915B2 (en) 2011-09-25 2016-02-23 Theranos, Inc. Systems and methods for diagnosis or treatment
US9664702B2 (en) 2011-09-25 2017-05-30 Theranos, Inc. Fluid handling apparatus and configurations
US8840838B2 (en) 2011-09-25 2014-09-23 Theranos, Inc. Centrifuge configurations
US8435738B2 (en) 2011-09-25 2013-05-07 Theranos, Inc. Systems and methods for multi-analysis
US9619627B2 (en) 2011-09-25 2017-04-11 Theranos, Inc. Systems and methods for collecting and transmitting assay results
US9250229B2 (en) 2011-09-25 2016-02-02 Theranos, Inc. Systems and methods for multi-analysis
CA2861124A1 (en) 2012-02-10 2013-08-15 Genentech, Inc. Single-chain antibodies and other heteromultimers
US9090694B2 (en) 2012-04-30 2015-07-28 Janssen Biotech, Inc. ST2L antibody antagonists
CA2878640A1 (en) 2012-07-13 2014-01-16 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
KR20140033986A (en) * 2012-09-11 2014-03-19 삼성전자주식회사 Protein complex for preparing bispecific antibodies and method using thereof
US20140178388A1 (en) * 2012-12-26 2014-06-26 Industrial Technology Research Institute Multivalent antibody fragments and trimerized complexes thereof
US9810704B2 (en) 2013-02-18 2017-11-07 Theranos, Inc. Systems and methods for multi-analysis
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
KR20160006168A (en) 2013-03-18 2016-01-18 바이오서오엑스 프로덕스 비.브이. Humanized anti-cd134(ox40) antibodies and uses thereof
CA2936962A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
WO2015142675A8 (en) 2014-03-15 2016-10-20 Novartis Ag Treatment of cancer using chimeric antigen receptor
US20170211055A1 (en) 2014-07-21 2017-07-27 Novartis Ag Sortase synthesized chimeric antigen receptors
WO2016014530A1 (en) 2014-07-21 2016-01-28 Novartis Ag Combinations of low, immune enhancing. doses of mtor inhibitors and cars
JP2017527271A (en) 2014-07-21 2017-09-21 ノバルティス アーゲー Treatment of cancer using human anti bcma chimeric antigen receptor
WO2016025880A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using gfr alpha-4 chimeric antigen receptor
US20170260268A1 (en) 2014-09-17 2017-09-14 Gregory Beatty Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
KR20170069257A (en) 2014-10-14 2017-06-20 노파르티스 아게 Antibody molecules to pd-l1 and uses thereof
WO2016090034A3 (en) 2014-12-03 2016-08-04 Novartis Ag Methods for b cell preconditioning in car therapy
KR20170134642A (en) 2015-04-08 2017-12-06 노파르티스 아게 Cd20 therapy, therapy cd22, cd19 and the chimeric receptor antigen (car) - the combination therapy of the expressing cells
WO2016172583A1 (en) 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
WO2017019894A8 (en) 2015-07-29 2017-11-09 Novartis Ag Combination therapies comprising antibody molecules to lag-3
GB201521383D0 (en) * 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521382D0 (en) * 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521393D0 (en) * 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521391D0 (en) * 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
WO2017106810A3 (en) 2015-12-17 2017-10-26 Novartis Ag Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof
WO2017106684A3 (en) 2015-12-17 2017-08-10 Janssen Biotech, Inc. Antibodies specifically binding hla-dr and their uses
WO2017125897A1 (en) 2016-01-21 2017-07-27 Novartis Ag Multispecific molecules targeting cll-1
US20170233472A1 (en) 2016-02-17 2017-08-17 Macrogenics, Inc. ROR1-Binding Molecules, and Methods of Use Thereof
WO2017149515A1 (en) 2016-03-04 2017-09-08 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
WO2017165683A1 (en) 2016-03-23 2017-09-28 Novartis Ag Cell secreted minibodies and uses thereof
WO2017181119A3 (en) 2016-04-15 2018-01-04 Novartis Ag Compositions and methods for selective protein expression

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (en) 1970-11-10 1977-09-15 Organon Nv Method for the detection and determination of laagmoleculire compounds and of proteins that can specifically bind these compounds, as well as the test pack.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241B1 (en) 1980-08-07 1988-10-18
DE3852304T3 (en) 1987-03-02 1999-07-01 Enzon Lab Inc Organism as a support for "Single Chain Antibody domain (SCAD)".
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
EP1279731B1 (en) 1991-03-01 2007-05-30 Dyax Corporation Process for the development of binding mini-proteins
DE768377T1 (en) 1988-09-02 1998-01-02 Dyax Corp Production and selection of Rekombinantproteinen with different binding sites
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68913658D1 (en) 1988-11-11 1994-04-14 Medical Res Council Cloning of immunoglobulin sequences from the variabelen domains.
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5270202A (en) 1989-11-03 1993-12-14 Syamal Raychaudhuri Anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1993010247A1 (en) 1991-11-20 1993-05-27 Ab Astra PHASMID VECTOR IN $i(E.COLI)
US5955341A (en) 1991-04-10 1999-09-21 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
DE4122599C2 (en) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid for antibody screening
ES2227512T3 (en) 1991-12-02 2005-04-01 Cambridge Antibody Technology Limited Production of antibodies against self-antigens from repertoires of antibody segments fixed in a phage.
US5348867A (en) 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
WO1993015210A1 (en) 1992-01-23 1993-08-05 Merck Patent Gmbh Monomeric and dimeric antibody-fragment fusion proteins
US5233409A (en) 1992-02-25 1993-08-03 Schwab Karl W Color analysis of organic constituents in sedimentary rocks for thermal maturity
GB9206318D0 (en) 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US5412087A (en) 1992-04-24 1995-05-02 Affymax Technologies N.V. Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
JP3720353B2 (en) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル Multivalent and multispecific binding proteins, their preparation and use
US5869337A (en) 1993-02-12 1999-02-09 President And Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
DE614989T1 (en) 1993-02-17 1995-09-28 Morphosys Proteinoptimierung A process for ligand binding in vivo selection of proteins.
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6165793A (en) 1996-03-25 2000-12-26 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5824483A (en) 1994-05-18 1998-10-20 Pence Inc. Conformationally-restricted combinatiorial library composition and method
US5738996A (en) 1994-06-15 1998-04-14 Pence, Inc. Combinational library composition and method
US5695941A (en) 1994-06-22 1997-12-09 The General Hospital Corporation Interaction trap systems for analysis of protein networks
EP0699755B1 (en) 1994-06-30 2004-04-28 Centro de Inmunologia Molecular Method for obtaining modified immunoglobulins with reduced immunogenicity of murine antibody variable domains, compositions containing them
GB9500851D0 (en) 1995-01-17 1995-03-08 Bionvent International Ab Method of selecting specific bacteriophages
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO1996032503A1 (en) 1995-04-11 1996-10-17 The General Hospital Corporation Reverse two-hybrid systems
DK1143006T3 (en) 1995-08-18 2008-07-14 Morphosys Ip Gmbh Vectors / DNA sequences from human combinatorial antibody libraries
US5695937A (en) 1995-09-12 1997-12-09 The Johns Hopkins University School Of Medicine Method for serial analysis of gene expression
FR2741892B1 (en) 1995-12-04 1998-02-13 Pasteur Merieux Serums Vacc Method of preparing a multicombinatorial library of antibody gene expression vectors, and expression systems bank antibody "coliclonaux" obtained
US6130037A (en) 1996-04-25 2000-10-10 Pence And Mcgill University Biosensor device and method
US6083693A (en) 1996-06-14 2000-07-04 Curagen Corporation Identification and comparison of protein-protein interactions that occur in populations
EP0929691B1 (en) 1996-09-24 2004-12-15 Cadus Pharmaceutical Corporation Methods and compositions for identifying receptor effectors
CA2304367C (en) 1997-09-16 2009-06-09 Fox Chase Cancer Center An improved yeast interaction trap assay
WO1999024455A1 (en) 1997-11-10 1999-05-20 The General Hospital Corporation Detection systems for registering protein interactions and functional relationships
CA2321262A1 (en) 1998-02-19 1999-08-26 President And Fellows Of Harvard College Monovalent, multivalent, and multimeric mhc binding domain fusion proteins and conjugates, and uses therefor
DE69933776D1 (en) 1998-09-07 2006-12-07 Glaxo Group Ltd GABA B receptor subtypes GABA B-R1c and GABA B R2 AND THEIR heterodimers
JP4312403B2 (en) 1999-07-20 2009-08-12 モルフォシス・アクチェンゲゼルシャフトMorphosys Ag (Poly) peptides / proteins, novel methods to be displayed on bacteriophage particles via disulfide bonds

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ARNDT ET AL.: "Helix-stabilized Fv (9hsFv) antibody fragments: substituting the constant domains of a Fab fragment for a heterodimeric coiled-coil domain", J. MOL. BIOL., vol. 312, 7 September 2001 (2001-09-07), pages 221 - 228, XP002967423 *
PLUCKTHUN ET AL.: "New protein engineering approaches to multivalent and bispecific antibody fragments", IMMUNOTECHNOLOGY, vol. 3, 1997, pages 83 - 105, XP004088466 *
See also references of EP1421117A4 *

Also Published As

Publication number Publication date Type
US20050009139A1 (en) 2005-01-13 application
US7429652B2 (en) 2008-09-30 grant
EP1421117B1 (en) 2013-01-09 grant
CN101654483A (en) 2010-02-24 application
WO2003012069A2 (en) 2003-02-13 application
CN1558916A (en) 2004-12-29 application
EP1421117A2 (en) 2004-05-26 application
EP1421117A4 (en) 2005-12-28 application
JP2005506064A (en) 2005-03-03 application
CA2455237A1 (en) 2003-02-13 application
JP2010053132A (en) 2010-03-11 application
CA2455237C (en) 2013-04-09 grant
US20030027247A1 (en) 2003-02-06 application
US6833441B2 (en) 2004-12-21 grant

Similar Documents

Publication Publication Date Title
WO2002088186A1 (en) Anti-cd40 monoclonal antibody
WO2004029207A3 (en) Optimized fc variants and methods for their generation
WO2004099249A3 (en) Optimized fc variants and methods for their generation
WO2002098869A3 (en) 1,4-disubstituted benzo-fused cycloalkyl urea compounds
WO2007062852A3 (en) ANTI-Aβ GLOBULOMER ANTIBODIES, ANTIGEN-BINDING MOIETIES THEREOF, CORRESPONDING HYBRIDOMAS, NUCLEIC ACIDS, VECTORS, HOST CELLS, METHODS OF PRODUCING SAID ANTIBODIES, COMPOSITIONS COMPRISING SAID ANTIBODIES, USES OF SAID ANTIBODIES AND METHODS OF USING SAID ANTIBODIES
WO2002000938A3 (en) Methods and compositions for transcription-based nucleic acid amplification
WO2003012100A3 (en) Method for the production of nucleic acids consisting of stochastically combined parts of source nucleic acids
WO2004097019A1 (en) Human antihuman interleukin-18 antibody, fragment thereof and method of using the same
WO2006106959A1 (en) Anti-cd-20 monoclonal antibody
WO2004058820A3 (en) Single-domain-effector group and its uses
WO2005111009A3 (en) Synthesis of amino acid keto-epoxides
WO2003044198A1 (en) Artificial antibody library with super-repertory
WO2006094192A3 (en) Humanized l243 antibodies
Huang et al. One-pot oligosaccharide synthesis: reactivity tuning by post-synthetic modification of aglycon
WO2002068698A3 (en) Use of nucleic acid libraries to create toxicological profiles
WO2003040133A1 (en) Maleic acid derivative and curable composition containing the same
WO2004020579A3 (en) Method of humanizing immune system molecules
WO2005001025A3 (en) Immunoglobulin chimeric monomer-dimer hybrids
WO2003074500A3 (en) N-aminoacetyl-pyrrolidine-2-carbonitriles and their use as ddp-iv inhibitors
WO2000041509A3 (en) Polypeptides having acid phosphatase activity and nucleic acids encoding same
WO2005002626A8 (en) Therapeutic phosphonate compounds
WO2006074267A3 (en) Distributed software construction for user interfaces
Choi et al. Engineering of immunoglobulin Fc heterodimers using yeast surface-displayed combinatorial Fc library screening
WO2003048208A3 (en) Expression control using variable intergenic sequences
WO2006023403A3 (en) Eph receptor fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ PH PL PT RO SD SE SG SI SK SL TJ TM TR TT TZ UG US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/001053

Country of ref document: MX

Ref document number: 2003517247

Country of ref document: JP

Ref document number: 2455237

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002327425

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002763414

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002818596X

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2002763414

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642